Matches in SemOpenAlex for { <https://semopenalex.org/work/W2777860661> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2777860661 abstract "Abstract Management of donor lymphocyte infusions (DLI) after reduced intensity conditioning regimen allogeneic hematopoietic stem cell transplantation (RICT) remains not clear and needs prospective studies. We performed a retrospective analysis on 47 patients (29 males and 18 females) who received 94 DLI among 96 patients who underwent RICT in our institution. Twenty-four patients received 1 DLI (D) [mean dose: 0.3x108 CD3 /Kg (0.01–1)] and 70 escalating doses (ED) [2 DLI (n=10), 3 DLI (n=9), 4 DLI (n=1), 5 DLI (n=1), 6 DLI (n=1) and 8 DLI (n=1)] from 0.1 to 5.6x108 CD3/Kg. The diagnosis pretransplant was acute leukemias (n=10) and myelodysplasia (n=3), chronic myeloid leukemia (n=2), Hodgkin (n=7) and non Hodgkin lymphomas (n=6), multiple myeloma (n=14) and solid tumours (n=5). Twenty patients have already been transplanted before RICT and 9 patients were in complete remission (CR), 19 in partial response (PR), 18 in evolutive disease (EDis). As hematopoietic stem cells, 22 patients received peripheral blood and 25 bone marrow and as conditioning 26 patients received busulfan, fludarabine and anti-thymocytes globulines (ATG), 13 patients TBI 2 grays associated to fludarabine (n=8) and 6 grays associated with cyclophosphamide (n=5), 5 patients received cyclophosphamide and ATG and 3 patients aracytine, idarubicine and fludarabine. After transplant and before any DLI, 21 developped acute GVHD (11 grade I, 8 grade II and 2 grade III). The indications and results after DLI are given in the Table 1. Only 4 patients received DLI for two different indications within time: 2 for relapse firstly and partial chimerism secondly and 2 according to protocol requirement firstly and for relapse secondly. After DLI, we noted 18 acute GVHD (7 grade I, 4 grade II, 6 grade III and 1 grade IV), 9 were resolutive after specific therapy and 18 patients developed chronic GVHD (13 limited and 5 extensive). Probability of overall survival at 2 years of patients who underwent RICT including DLI (n=47) was significantly better than for patients undergoing RICT without DLI (n=57) [43% (95%CI 30.5–60.4) vs 31.5 (95%CI 18.8–52.8) (p=0.01)] but there was no difference when we consider EFS [20.7% (95%CI 11.6–36.8) vs 21.6% (11–42.5) (p=0.49)]. We performed for patients receiving DLI a multivariate analysis stratified on diagnosis studying sex, age, status at transplant and mean dose of infused lymphocytes and we demonstrated that lymphocyte dose had a significant negative impact on EFS (HR= 1.06 95% CI 1.01–1.10) (p=0.01). To better understand the real place of DLI within allogeneic immunotherapy against malignancies, we need more details about the results of DLI in retrospective analysis but principally prospective studies in the future. TABLE 1 Indication of DLI Nb of patients Nb of DLI DLI (D) DLI (ED) Dose x 10 exp8 CD3/Kg Response to DLI Evolutive Disease N = 34 23 2.26 10 13 1.46 EDis 5 1.6 2 3 0.66 CR 6 1.5 2 4 0.45 PR Mixed Chimerism N = 7 6 1.5 5 1 0.7 Total Donor 1 1 1 0 0.7 Mixed Chimerism Protocol N = 6 1 1 1 0 0.1 CR 3 1.6 2 1 0.34 PR 2 2 1 2 0.52 EDis" @default.
- W2777860661 created "2018-01-05" @default.
- W2777860661 creator A5005045049 @default.
- W2777860661 creator A5019277748 @default.
- W2777860661 creator A5026018104 @default.
- W2777860661 creator A5037448560 @default.
- W2777860661 creator A5055128673 @default.
- W2777860661 creator A5057172167 @default.
- W2777860661 creator A5068217025 @default.
- W2777860661 creator A5070792872 @default.
- W2777860661 creator A5072027146 @default.
- W2777860661 creator A5072412716 @default.
- W2777860661 creator A5079529581 @default.
- W2777860661 creator A5081112781 @default.
- W2777860661 creator A5082189560 @default.
- W2777860661 creator A5082580803 @default.
- W2777860661 creator A5087870886 @default.
- W2777860661 date "2004-11-16" @default.
- W2777860661 modified "2023-10-14" @default.
- W2777860661 title "Donor Lymphocyte Infusion Management and Impact on Transplant Outcome after Reduced Intensity Conditioning Allogeneic Transplantation." @default.
- W2777860661 doi "https://doi.org/10.1182/blood.v104.11.2305.2305" @default.
- W2777860661 hasPublicationYear "2004" @default.
- W2777860661 type Work @default.
- W2777860661 sameAs 2777860661 @default.
- W2777860661 citedByCount "0" @default.
- W2777860661 crossrefType "journal-article" @default.
- W2777860661 hasAuthorship W2777860661A5005045049 @default.
- W2777860661 hasAuthorship W2777860661A5019277748 @default.
- W2777860661 hasAuthorship W2777860661A5026018104 @default.
- W2777860661 hasAuthorship W2777860661A5037448560 @default.
- W2777860661 hasAuthorship W2777860661A5055128673 @default.
- W2777860661 hasAuthorship W2777860661A5057172167 @default.
- W2777860661 hasAuthorship W2777860661A5068217025 @default.
- W2777860661 hasAuthorship W2777860661A5070792872 @default.
- W2777860661 hasAuthorship W2777860661A5072027146 @default.
- W2777860661 hasAuthorship W2777860661A5072412716 @default.
- W2777860661 hasAuthorship W2777860661A5079529581 @default.
- W2777860661 hasAuthorship W2777860661A5081112781 @default.
- W2777860661 hasAuthorship W2777860661A5082189560 @default.
- W2777860661 hasAuthorship W2777860661A5082580803 @default.
- W2777860661 hasAuthorship W2777860661A5087870886 @default.
- W2777860661 hasConcept C126322002 @default.
- W2777860661 hasConcept C141071460 @default.
- W2777860661 hasConcept C2776364478 @default.
- W2777860661 hasConcept C2776694085 @default.
- W2777860661 hasConcept C2776755627 @default.
- W2777860661 hasConcept C2777408962 @default.
- W2777860661 hasConcept C2778880498 @default.
- W2777860661 hasConcept C2779263901 @default.
- W2777860661 hasConcept C2779695342 @default.
- W2777860661 hasConcept C2780611847 @default.
- W2777860661 hasConcept C2911091166 @default.
- W2777860661 hasConcept C71924100 @default.
- W2777860661 hasConcept C90924648 @default.
- W2777860661 hasConceptScore W2777860661C126322002 @default.
- W2777860661 hasConceptScore W2777860661C141071460 @default.
- W2777860661 hasConceptScore W2777860661C2776364478 @default.
- W2777860661 hasConceptScore W2777860661C2776694085 @default.
- W2777860661 hasConceptScore W2777860661C2776755627 @default.
- W2777860661 hasConceptScore W2777860661C2777408962 @default.
- W2777860661 hasConceptScore W2777860661C2778880498 @default.
- W2777860661 hasConceptScore W2777860661C2779263901 @default.
- W2777860661 hasConceptScore W2777860661C2779695342 @default.
- W2777860661 hasConceptScore W2777860661C2780611847 @default.
- W2777860661 hasConceptScore W2777860661C2911091166 @default.
- W2777860661 hasConceptScore W2777860661C71924100 @default.
- W2777860661 hasConceptScore W2777860661C90924648 @default.
- W2777860661 hasLocation W27778606611 @default.
- W2777860661 hasOpenAccess W2777860661 @default.
- W2777860661 hasPrimaryLocation W27778606611 @default.
- W2777860661 hasRelatedWork W1955322177 @default.
- W2777860661 hasRelatedWork W2374949105 @default.
- W2777860661 hasRelatedWork W2414781517 @default.
- W2777860661 hasRelatedWork W2490593272 @default.
- W2777860661 hasRelatedWork W2593968947 @default.
- W2777860661 hasRelatedWork W2609272607 @default.
- W2777860661 hasRelatedWork W2979354104 @default.
- W2777860661 hasRelatedWork W3123349251 @default.
- W2777860661 hasRelatedWork W3212134050 @default.
- W2777860661 hasRelatedWork W3213199609 @default.
- W2777860661 isParatext "false" @default.
- W2777860661 isRetracted "false" @default.
- W2777860661 magId "2777860661" @default.
- W2777860661 workType "article" @default.